Table 1.
Baseline characteristics and transfer data of COVID-19 patients admitted to the Hospital at Home the study period (N = 63)
| Baseline characteristics | |
| Age, years (median, IQR) | 51 (40–62) |
| Female sex, n (%) | 34 (54) |
| Smoker, n (%) | |
| No | 54 (85.7) |
| Former | 5 (7.9) |
| Active | 4 (6.3) |
| Dyslipidaemia, n (%) | 10 (15.9) |
| Diabetes mellitus, n (%) | 6 (9.5) |
| Hypertension, n (%) | 11 (17.5) |
| Drug treatment, n (%) | 10 (15.9) |
| ACEi | 3 (4.8) |
| ARB | 2 (3.2) |
| CA | 2 (3.2) |
| Diuretics | 2 (3.2) |
| Other | 1 (1.6) |
| Chronic lung disease, n (%) | 4 (6.3) |
| Ischemic heart disease, n (%) | 3 (4.8) |
| Moderate–severe chronic renal failure, n (%) | 2 (3.2) |
| Moderate–severe chronic liver disease, n (%) | 1 (1.6) |
| Neoplasm, n (%) | 4 (6.3) |
| Data at Hospital at home admission | |
| Department of referral, n (%) | |
| ED | 25 (39.7) |
| Ward | 32 (50.8) |
| Other | 6 (9.5) |
| Number of live-in partners at home, median (IQR) | 1 (1–2) |
| Nasopharyngeal swab for SARS-CoV-2, n (%) | 60 (95.2) |
| Days after admission, median (IQR) | 0 (−0.5 to 1) |
| Days after symptoms onset, median (IQR) | 6 (3–8) |
| Positive PCR, n (%) | 57 (90.5) |
| Total length of stay in days, median (IQR) | 7 (3.8–10.2) |
| Length of stay at HAH days, median (IQR) | 6 (4–8) |
ACEi Angyotensin converter enzyme inhibitors, ARB Angyotensin II receptor blockers, CA calcium antagonists, ED emergency department, HaH hospital at home, PCR polymerase-chain reaction